Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
To the Editor:
In the Controlled Study of Lanreotide Antiproliferative Response in Neuroendocrine Tumors (CLARINET), Caplin et al. (July 17 issue)
1
report that lanreotide prolonged progression-free survival in patients with grade 1 and selected grade 2 neuroendocrine tumors (hazard ratio for progression or death, 0.47; 95% confidence inte...
Alternative Titles
Full title
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1613949450
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1613949450
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMc1409757
